Randomized trial · people

Teriparatide: fewer new vertebral fractures than risedronate in VERO

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this head-to-head trial, teriparatide led to fewer new spine and clinical fractures than risedronate over 24 months in severe post-menopausal osteoporosis, while the difference in non-vertebral fractures was not significant.

Kind
Randomized trial
Studied in
People
Published
2018
Journal
Lancet

What they tested

The team tested whether teriparatide prevents new fractures better than risedronate in women with severe osteoporosis after menopause.

How the study was done

A double-blind, double-dummy randomized controlled trial at many centers. Each group had 680 post-menopausal women who already had vertebral (spine) fractures and low bone density. One group got daily teriparatide 20 μg shots plus a weekly dummy pill. The other got weekly risedronate 35 mg pills plus daily dummy shots, for 24 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

After 24 months, a new spine fracture showed up on X-ray in 28 (5.4%) of 680 women on teriparatide and in 64 (12.0%) of 680 on risedronate, a risk ratio of 0.44. Clinical fractures, meaning non-vertebral fractures plus spine fractures that caused symptoms, were also less common with teriparatide: 30 (4.8%) vs 61 (9.8%), a hazard ratio of 0.48. Non-vertebral fragility fractures happened in 25 (4.0%) women on teriparatide and 38 (6.1%) on risedronate, but this gap was not statistically significant (p=0.10).

What it doesn’t show

Only post-menopausal women with severe osteoporosis and existing spine fractures took part, so the results may not apply to milder cases or to men. The study was funded by Lilly.

The paper

Kendler et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo